Affiliation:
1. Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO
Abstract
Abstract
Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen receptor T-cell (CAR-T) therapy now presenting a curative option for a subset of those patients. However, with the approval of several novel bispecific monoclonal antibody (BsAb) therapies with considerable activity in R/R aggressive large B-cell lymphomas (LBCL), patients and oncologists will be faced with decisions regarding how to sequence CAR-T and BsAb therapies based on patient- and disease-related factors. In this review, we compare CAR-T and BsAb therapies for R/R LBCL, highlighting data on the efficacy and toxicity of each treatment paradigm, and provide a roadmap for sequencing these highly effective therapies.
Publisher
American Society of Hematology
Reference52 articles.
1. 5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1) [published online February 23, 2023];Neelapu;Blood
2. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy;Chong;N Engl J Med,2021
3. How I treat cytopenias after CAR T-cell therapy;Jain;Blood,2023
4. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma;Maloney;J Hematol Oncol,2021
5. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma;Neelapu;N Engl J Med,2017